Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.41 |
| ▸ | LSS | P48449 | 2/20 | 0.37 |
| ▸ | GUSB | P08236 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561240 | 0.93 | DPP4 (0.37) | GNAO1GNAI3GNAI1SLC6A3 | |
| SCHEMBL12560837 | 0.93 | DPP4 (0.37) | GNAO1GNAI3GNAI1SLC6A3 | |
| SCHEMBL19984466 | 0.85 | SLC6A3 (0.44) | GNAO1GNAI3GNAI1SLC6A3 | |
| SCHEMBL13906059 | 0.85 | SLC6A3 (0.44) | GNAO1GNAI3GNAI1SLC6A3 | |
| SCHEMBL19984469 | 0.85 | SLC6A3 (0.44) | GNAO1GNAI3GNAI1SLC6A3 | |
| SCHEMBL19578801 | 0.79 | GUSB (0.47) | LSSGUSBGBA1 | |
| SCHEMBL8506753 | 0.79 | GNAO1 (0.43) | GNAO1GNAI3GNAI1LSSGUSB | |
| SCHEMBL22252594 | 0.77 | NCF1 (0.37) | SLC6A3 | |
| SCHEMBL20688084 | 0.77 | NCF1 (0.37) | SLC6A3 | |
| SCHEMBL12561291 | 0.77 | NCF1 (0.37) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | GNAO1 2509/4885GNAI3 1184/4885GNAI1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.